SBIR-STTR Award

3D Shear-wave Imaging Transducer for Liver Cancer Screening
Award last edited on: 4/17/2023

Sponsored Program
SBIR
Awarding Agency
NIH : NIBIB
Total Award Amount
$399,617
Award Phase
1
Solicitation Topic Code
286
Principal Investigator
Stephen Barnes

Company Information

Acoustiic Inc

1365 Avenida De Cortez
Pacific Palisades, CA 90272
   (425) 219-9811
   N/A
   www.acoustiic.com
Location: Single
Congr. District: 32
County: Los Angeles

Phase I

Contract Number: 1R43EB029880-01A1
Start Date: 9/16/2022    Completed: 9/15/2023
Phase I year
2022
Phase I Amount
$399,617
Liver cancer is one of the leading causes of cancer death worldwide and is expected to account for an increasingpercentage of cancer deaths in the United States, with hepatocellular carcinoma (HCC) accounting for approxi-mately 80% of liver cancer cases. Treatment options for HCC vary with the stage of detection, with early detec-tion leading to substantial improvement in survival rates. Unfortunately, current surveillance techniques for HCChave low sensitivity. Standard B-mode ultrasound is the recommended surveillance method, however, the sen-sitivity of ultrasound for detection of HCC depends upon the size of the nodule, the background coarseness incirrhotic livers, and patient body habitus. Reported HCC lesion detection rates during 2D B-mode ultrasonicimaging range from 58-89%, with much lower detection rates found for small focal liver lesions in cirrhotic livers.CT and MRI are used for confirmation after a suspicious region has been identified with ultrasound, but thesemodalities are not cost-effective for surveillance, and in the case of CT, pose additional radiation risk.Commercial 2D ultrasonic shear wave elasticity imaging (SWEI) measurements have been shown by numerousgroups to have significantly higher contrast for HCC than B-mode imaging and have demonstrated success inhepatic lesion visualization. However, these systems have challenges arising from limited acoustic output, withrespect to frame rate, penetration depth, measurement heterogeneity in stiffer livers. Complete volume assess-ment of the liver with 2D imaging also extends exam time. These limitations preclude its use for widespreadHCC screening.This work will address these limitations by developing a high-power matrix array capable of wide field-of-view3D SWEI imaging, with additional 'push' capability that will enable rapid SWEI assessment of the full liver volume.To achieve the clinical objective, this project will initially develop 3D SWEI research prototype transducers, aprerequisite for the full development of 3D SWEI methods and applications.The prototypes developed in this project will enable development of 3D SWEI imaging methods, developmentand validation of the HCC screening application. This will provide a powerful tool for high contrast HCC screeningand treatment monitoring leading to an effective method for liver cancer screening, allowing early diagnosis andintervention, yielding substantial improvements in survival rate.

Public Health Relevance Statement:
Project Narrative Liver cancer is one of the leading causes of cancer death world-wide, and accounts for an increasing percentage of cancer deaths in the United States. This project will lead to a cost effective, reliable method for liver cancer screening, allowing early diagnosis and intervention, yielding substantial improvements in survival rate. The project will develop advanced diagnostic ultrasound hardware for volumetric imaging of the mechanical stiffness of the liver which has demonstrated success in cancer lesion visualization. This advanced hardware will enable development of the imaging methods and clinical application for liver cancer screening.

Project Terms:

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----